Partial
Partially Aligned
Patient Risk:
Low
Summary
Some clinical/usage claims (brand/active ingredient, indication, thin-layer twice-daily application) are consistent with the provided FDA label excerpts, but non-label-specific statements about South Africa distribution, OTC availability, and pricing/intellectual property are not supported by the supplied prescribing information and are therefore unsupported/absent.
Category Scores
Accurate Statements
Eucrisa is the brand name for crisaborole.
Provided label excerpts identify EUCRISA and active ingredient crisaborole (Drug/active ingredient section; label sections 1/12).
Crisaborole is a topical medicine used for atopic dermatitis (eczema).
Label Indications and Usage (1): topical treatment of mild to moderate atopic dermatitis.
Eucrisa is applied as a thin layer to the affected skin areas.
Label Dosage and Administration (2): apply a thin layer twice daily to affected areas.
Unsupported Statements
In South Africa, Eucrisa is typically found through dermatology channels and prescription distribution rather than over-the-counter pharmacy shelves.
The supplied prescribing information excerpts do not address country-specific distribution channels or OTC vs prescription availability.
Eucrisa is used for eczema management in eligible patients as directed by a South African prescriber.
The label excerpt supports that EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in eligible patients, but it does not support South Africa-specific prescriber language (jurisdictional/regulatory/distribution detail absent).
Availability of Eucrisa in South African pharmacies can vary by pharmacy and supplier stock.
The supplied prescribing information excerpts do not discuss pharmacy-level stock variability or availability factors.
Drug availability and pricing can be influenced by intellectual property status and market approvals.
The supplied prescribing information excerpts do not discuss intellectual property or pricing determinants.
Contradictions
Low
AI Statement
—
Label Reference
Important Omissions
If evaluating dosing accuracy: label also states twice daily application, and consideration of reducing to once daily after clinical effect is achieved; the provided response did not mention twice-daily frequency or the once-daily-after-effect consideration explicitly (only 'thin layer' was stated).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported statements relate to distribution/availability/pricing rather than contraindications, warnings, dosing safety, or adverse effects. The only supported clinical-use detail provided is consistent with the label (thin-layer application for atopic dermatitis).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Non-label-specific, jurisdictional/distribution and pricing/intellectual-property statements are not supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Restrict claims to label-supported content (indication and topical application instructions). Remove or clearly qualify statements about South Africa-specific distribution/OTC status and pricing/availability drivers unless supported by separate, non-prescribing-information sources.